Bionano Genomics - BNGO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 540.41%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.62
▲ +0.03 (5.05%)

This chart shows the closing price for BNGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bionano Genomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNGO

Analyst Price Target is $4.00
▲ +540.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bionano Genomics in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 540.41% upside from the last price of $0.62.

This chart shows the closing price for BNGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in Bionano Genomics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024BTIG ResearchLower TargetBuy ➝ Buy$3.00 ➝ $2.00Low
3/7/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$7.00 ➝ $6.00Low
11/13/2023Maxim GroupReiterated RatingBuy ➝ HoldLow
8/10/2023BTIG ResearchBoost TargetBuy ➝ Buy$10.00Low
5/18/2023BTIG ResearchLower Target$30.00 ➝ $20.00Low
5/10/2023LADENBURG THALM/SH SHLower Target$60.00 ➝ $48.00Low
2/6/2023OppenheimerLower TargetOutperform$120.00 ➝ $90.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$40.00Low
12/12/2022BTIG ResearchReiterated RatingBuy$35.00Low
7/18/2022OppenheimerReiterated RatingOutperform$120.00Low
4/7/2022BTIG ResearchLower TargetBuy$100.00 ➝ $70.00High
12/30/2021OppenheimerReiterated RatingOutperform ➝ Outperform$140.00Medium
11/5/2021Maxim GroupInitiated CoverageBuy$120.00Low
6/16/2021BTIG ResearchInitiated CoverageBuy$100.00High
3/24/2021OppenheimerReiterated RatingBuyHigh
2/8/2021OppenheimerBoost Target$15.00 ➝ $150.00Low
1/22/2021Maxim GroupBoost Target$20.00 ➝ $140.00High
12/4/2020Roth CapitalDowngradeBuy ➝ NeutralLow
9/24/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.50Medium
8/24/2020OppenheimerReiterated RatingBuyHigh
8/17/2020Maxim GroupInitiated CoverageBuy$20.00Medium
7/24/2020Maxim GroupReiterated RatingBuy$20.00High
7/17/2020Maxim GroupReiterated RatingBuy$20.00High
7/10/2020Maxim GroupInitiated CoverageBuy$20.00High
6/11/2020OppenheimerReiterated RatingBuy$15.00Medium
6/4/2020Roth CapitalReiterated RatingBuy$10.00High
4/19/2020OppenheimerInitiated CoverageOutperform$15.00Medium
4/8/2020OppenheimerInitiated CoverageOutperform$15.00High
4/1/2020Roth CapitalReiterated RatingBuyLow
4/1/2020Maxim GroupReiterated RatingBuy$30.00High
3/11/2020Maxim GroupReiterated RatingBuy$30.00High
12/6/2019Maxim GroupReiterated RatingBuy$30.00High
11/8/2019Maxim GroupReiterated RatingBuy$30.00Low
8/9/2019Maxim GroupReiterated RatingBuy$70.00Medium
7/31/2019Maxim GroupSet TargetBuy$70.00N/A
(Data available from 7/23/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/25/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/24/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/25/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/24/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Bionano Genomics logo
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.62
Low: $0.58
High: $0.63

50 Day Range

MA: $0.81
Low: $0.55
High: $1.15

52 Week Range

Now: $0.62
Low: $0.52
High: $6.19

Volume

1,429,182 shs

Average Volume

1,562,646 shs

Market Capitalization

$41.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Bionano Genomics?

The following equities research analysts have issued reports on Bionano Genomics in the last year: BTIG Research, Maxim Group, and Scotiabank.
View the latest analyst ratings for BNGO.

What is the current price target for Bionano Genomics?

2 Wall Street analysts have set twelve-month price targets for Bionano Genomics in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 540.4%. Scotiabank has the highest price target set, predicting BNGO will reach $6.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $2.00 for Bionano Genomics in the next year.
View the latest price targets for BNGO.

What is the current consensus analyst rating for Bionano Genomics?

Bionano Genomics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BNGO.

What other companies compete with Bionano Genomics?

How do I contact Bionano Genomics' investor relations team?

Bionano Genomics' physical mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company's listed phone number is (858) 888-7600 and its investor relations email address is [email protected]. The official website for Bionano Genomics is www.bionanogenomics.com. Learn More about contacing Bionano Genomics investor relations.